Insulet Corporation entered into the Ninth Amendment to its Credit Agreement on September 21, 2026. The amendment replaced $475 million in existing term loans with new term loans at par, reducing the interest rate margin by 0.25% for both base rate and term SOFR loans. Additionally, revolving credit commitments were increased by $250 million, raising the total facility size to $750 million, while the applicable interest rate margins for revolving loans were reduced from 1.50%-2.00% to 1.25%-1.75%. Proceeds were used to refinance existing debt and pay accrued interest. Insulet Corporation operates in the medical device industry, specializing in insulin delivery systems.
